Acurx Pharmaceuticals (NASDAQ:ACXP) Announces Earnings Results

Acurx Pharmaceuticals (NASDAQ:ACXP) released its earnings results on Tuesday. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06, Zacks reports. During the same period last year, the company posted ($0.24) earnings per share.

Acurx Pharmaceuticals Stock Performance

ACXP stock traded down $0.05 during trading on Thursday, hitting $1.77. The stock had a trading volume of 47,480 shares, compared to its average volume of 90,250. The company’s 50 day moving average price is $1.96 and its two-hundred day moving average price is $2.14. Acurx Pharmaceuticals has a 1-year low of $1.52 and a 1-year high of $5.28. The stock has a market cap of $28.76 million, a price-to-earnings ratio of -1.62 and a beta of -1.73.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Acurx Pharmaceuticals in a research note on Thursday.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.